Inclusion Criteria:

          -  Signed written informed consent obtained prior to study procedures

          -  Patients ≥18 years with an ECOG 0 or 1 (Parts 1 and 2) or 0-2 (Part 3).

          -  Relapsed/Refractory (R/R) or locally advanced, unresectable solid tumor for which no
             standard therapy exists (Parts 1 and 2), or for which the patient is ineligible or has
             declined standard therapyR/R, cytologically confirmed AML (Part 3).

          -  Disease must be measurable per Response Evaluation Criteria

          -  The shorter of 28 days or 5 half-lives must have elapsed since the completion of prior
             therapy, before initiation of study treatment.

          -  Adequate Organ Function as Defined by the protocol:

               -  GFR ≥ 50 mL/min/1.73,

               -  AST and ALT ≤ 3 × the ULN and total bilirubin ≤ 1.5 × ULN,

               -  In the absence of cancer within the liver, or AST and ALT ≤ 5 × ULN and total
                  bilirubin ≤ 3 × ULN, in the setting of primary or metastatic liver tumors.

               -  ANC ≥ 10 × 103/μL and platelet count ≥ 100 × 103/μL without myeloid growth factor
                  support or transfusion, respectively, for at least one week.

               -  Hemoglobin should be ≥ 9 g/dL without red blood cell transfusion for at least two
                  weeks.

               -  Patients must have LVEF ≥ 45%

          -  Patients enrolling into Part 2 of the study must be diagnosed with a solid tumor that
             has been selected for an expansion cohort

        Exclusion Criteria:

          -  Primary central nervous system (CNS) malignancy or CNS involvement, unless
             asymptomatic, previously treated, and stable without steroids (Parts 1 and 2) or known
             CNS leukemia (Part 3).

          -  Known hypersensitivity to any component of study treatment or excipients.

          -  Positive antibody screen using institution's standard type and screen test.

          -  Clinically significant, active and uncontrolled infection, including human
             immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV).

          -  Clinically significant coagulopathy, uncontrolled hypertension or autoimmune hemolytic
             anemia

          -  Leukemic blast count ≥25 x 103/µL (Part 3)

          -  Concomitant conditions requiring active immunosuppression

          -  Grade 3 immune related Adverse Event (irAE)

          -  Prior malignancy within the past 3 years, with protocol specified exceptions